Abstract 88P
Background
It is now clear that the immune system has a substantial effect on the progression of colon cancer. Typically, an immune response defined by a polarized Th1 phenotype, characterized by expression of CXCR3/CCR5 chemokine-receptor ligands, activation of interferon stimulated genes and production of cytotoxic molecules by effector immune cells, has been associated with immune-mediated tumor rejection. We have previously introduced a gene signature, called Immunology Constant of Rejection (ICR), that reflects these immune components. This signature was able to differentiate quite well the patients with an active immune environment and improved survival vs those who did not display this phenotype. This phenomenon although expected based on other immune infiltration studies could not be observed in the TCGA colon cancer cohort, likely due to the per protocol exclusion of samples with low purity. To gain more insight in the underlying mechanism of cancer tissue rejection by the immune system, we build an extensive data repository from high quality colon cancer samples unbiased for tumor purity.
Methods
RNA and DNA were isolated from fresh frozen tissue samples of a cohort of 366 colon cancer patients collected over the last decade at the University of Leiden, Netherlands. Tissue sections flanking the corresponding samples were hematoxylin and eosin stained. RNA-seq (HiSeq4000) data was obtained using HISAT2 alignment and quantile normalization of the GC corrected raw counts. Whole Exome Sequencing (>100X) for our cohort for normal and cancer tissue respectively. T-cell repertoire profiling of 150 tumors was achieved using Adaptive immunoSEQ. Tumor immune phenotype classification was done using unsupervised consensus clustering based on the expression of ICR genes.
Results
Our preliminary data supports a positive impact of ICR gene expression in our colon cancer cohort: patients in ICR High cluster had a significantly improved survival compared to other clusters.
Conclusions
This newly generated immune centric NGS dataset, generated in Qatar, will is used to elucidate the genetic determinants of immune phenotype in colon cancer and the relationship of the immune phenotype, the tumors genetics the TCR diversity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sidra Medicine.
Funding
Qatar National Research Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract